NCT05594784View on ClinicalTrials.gov

Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

October 8, 2022

Primary Completion Date

March 25, 2025

Study Completion Date

March 25, 2025

Conditions
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Interventions
DRUG

Olverembatinib

a third-generation TKI

DRUG

Venetoclax

a selective inhibitor of B-cell lymphoma 2 (Bcl-2)

DRUG

prednisone

Glucocorticoids

DRUG

Vincristine

Anti-tumor alkaloids

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER